Isoxazolines are first-line treatment for canine generalized demodicosis, with fluralaner, sarolaner, and afoxolaner all demonstrating >98% mite count reduction within 56–84 days of monthly oral dosing.BMC Veterinary…+1
Treatment should continue until two consecutive monthly skin scrapings are negative for live mites, then extended for an additional 2 months beyond that endpoint to prevent recurrence.Veterinary Derm… Deep skin scrapings of the same sites performed monthly remain the monitoring standard throughout treatment.Veterinary Derm…
Fluralaner (oral, 25–56 mg/kg) administered at the labeled flea/tick dose achieves 98.9% mite count reduction by day 28 and eliminates mites from skin scrapings by day 56 in all treated dogs.Parasites and V… In a large field trial, parasitological cure — defined as two negative skin scrapings one month apart — was achieved in 81% of adult-onset cases by 2 months and 100% by 4 months, and in 81% of juvenile-onset cases by 2 months and 100% by 3 months, with no adverse effects observed.Veterinary Derm… A single oral dose of fluralaner (25–50 mg/kg) successfully eliminated generalized demodicosis in 66 of 67 dogs with adequate follow-up.Journal of the… A single oral or spot-on fluralaner treatment was also evaluated against imidacloprid-moxidectin in a European field study, with treatment considered efficacious when >90% of dogs were free of live mites at both days 56 and 84.Parasites and V…
Sarolaner (oral, 2–4 mg/kg monthly) achieves parasitological cure in 92.9% of dogs after three monthly treatments and 100% after five monthly treatments.Veterinary Derm… Mite counts are reduced by 77.2% on day 30, 95.0% on day 60, 98.5% on day 90, and 99.0% on day 120, reaching 100% by days 150 and 180.Veterinary Derm… Affected body surface area decreases by 94% with sarolaner versus 72% with imidacloprid-moxidectin.Veterinary Derm… The combination product sarolaner + moxidectin + pyrantel (SMP, monthly oral) reduces mite counts by 88.8% on day 14, 99.2% on day 29, and eliminates all live mites by day 42 in laboratory conditions; in field conditions, 100% mite elimination is achieved by day 90 at the latest.Veterinary Derm…
Afoxolaner (oral, ≥2.5 mg/kg) administered on days 0, 14, 28, and 56 achieves 99.2% mite count reduction by day 28, 99.9% by day 56, and 100% by day 84.Journal of the… Monthly afoxolaner over three doses reduces mite counts by 87.6% on day 28, 96.5% on day 56, and 98.1% on day 84, with all treatments well tolerated.Parasites and V…
Imidacloprid/moxidectin spot-on (2.5/10 mg/kg) applied weekly is an established alternative, achieving negative skin scrapings in 6 of 11 dogs by week 4 and clinical remission in 90.1% of dogs with hyperadrenocorticism-associated demodicosis, maintained through 12-month follow-up.Acta Veterinari… In the sarolaner non-inferiority trial, imidacloprid-moxidectin achieved parasitological cure in 77.3% of dogs after 3 months and 91.7% after 6 months — slower than sarolaner.Veterinary Derm…
Doramectin (0.6 mg/kg SC weekly) is an effective macrocyclic lactone option, achieving remission in 94.8% of dogs with a mean treatment duration of 7.1 weeks and adverse events in only 0.5% of cases.Veterinary Derm… Oral doramectin at 600 µg/kg twice weekly achieves a 92% success rate versus 81% for weekly subcutaneous injection, with mean time to negative skin scrapings of 12 and 13 weeks respectively — no statistically significant difference between routes.Veterinary Derm… Ivermectin is included among evidence-supported options but is not recommended as first-choice treatment.BMC Veterinary…
Systemic antibiotics for concurrent pyoderma do not significantly shorten the duration of miticidal therapy or time to microscopic remission, though secondary bacterial infections are common and should be managed clinically.Veterinary Para… Dogs with furunculosis have significantly higher mite burdens at presentation but do not have a significantly different duration to microscopic remission compared to dogs without furunculosis.Veterinary Para…
Therapeutic selection should be guided by local drug licensing, drug availability, and individual case parameters.Veterinary Derm… In young dogs with generalized demodicosis, affected individuals should not be bred due to suspected genetic and immunological contributions to pathogenesis.Veterinary Derm… In adult-onset cases, an underlying immunosuppressive condition should be investigated and addressed.Veterinary Derm…+1
| Drug | Dose & Route | Efficacy | Key Caveat |
|---|---|---|---|
| Fluralaner | 25–56 mg/kg PO (single or monthly) | 98.9% mite reduction by day 28; 100% cure by day 56–84 | Labeled for flea/tick; extralabel for demodicosis in many regions |
| Sarolaner | 2–4 mg/kg PO monthly | 92.9% cure after 3 treatments; 100% after 5 | Slower initial reduction vs. afoxolaner |
| SMP (sarolaner + moxidectin + pyrantel) | Monthly PO | 100% mite elimination by day 42 (lab); day 90 (field) | Combination product |
| Afoxolaner | ≥2.5 mg/kg PO (days 0, 14, 28, 56) | 99.2% reduction day 28; 100% by day 84 | Labeled for demodicosis in Europe |
| Imidacloprid/moxidectin | 2.5/10 mg/kg spot-on weekly | 90.1% remission; 91.7% cure at 6 months | Slower than isoxazolines; weekly application burden |
| Doramectin | 0.6 mg/kg SC weekly or 0.6 mg/kg PO twice weekly | 94.8% (SC); 92% (oral) remission | Not licensed for demodicosis; MDR1 mutation risk |
| Ivermectin | 600 µg/kg PO q24h | Effective but not first-choice | Narrow safety margin; MDR1 risk |
Would you like guidance on managing treatment-refractory cases or adult-onset demodicosis with concurrent immunosuppressive disease?